| For: | Mondal S, Pappachan JM. Current perspectives and the future of disease-modifying therapies in type 1 diabetes. World J Diabetes 2025; 16(1): 99496 [PMID: 39817218 DOI: 10.4239/wjd.v16.i1.99496] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v16/i1/99496.htm |
| Number | Citing Articles |
| 1 |
Tinglin Lu, Weidong Qiang, Qingqing Ye. Cytokines and chemokines in diabetes: Immunopathogenesis, therapeutic targets, and future perspectives across all disease forms. Pathology - Research and Practice 2026; 282 doi: 10.1016/j.prp.2026.156466
|
| 2 |
Ramtin Naderian, Samira Mehrabipari, Mohammad Amin Hemmati, Majid Eslami. Exploring the pathophysiological links between obesity, diabetes, and myocardial dysfunction: an in-depth narrative review. Journal of Diabetes & Metabolic Disorders 2025; 24(2) doi: 10.1007/s40200-025-01802-6
|
| 3 |
Alfonso Galderisi, Colin M. Dayan, Helen M. Colhoun, Justin M. Gregory. Relevance of Quantitative Measures of Beta-Cell Function in Clinical Practice. Hormone Research in Paediatrics 2026; doi: 10.1159/000552501
|
| 4 |
Shuo Yang, Shanshan Zhu, Xinwen Yu, Wencheng Zhang, Xin Wang, Yuxin Jin, Weiting Wang, Guohong Zhao, Bin Gao. 4-Methylumbelliferone for type 1 diabetes therapy: evidence for β-cell protection via EGFR/PI3K/Akt signaling. Journal of Endocrinological Investigation 2026; doi: 10.1007/s40618-026-02964-7
|